VivoSeq
Neurology

Tourette Syndrome

32

Pipeline Programs↗

4

Active Trials↗

22

Companies Involved↗

Tourette syndrome is a moderately active landscape with 32 programs across 22 companies. The most active players are Auspex Pharmaceuticals, Inc., Edison Pharmaceuticals Inc, Pfizer. 9 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

15/100

Mech. Concentration

8/100

Completion Rate

77/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Auspex Pharmaceuticals, Inc.

1 program

Phase 1E

Edison Pharmaceuticals Inc

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1Neurocrine Biosciences logo

Neurocrine Biosciences

2 programs

Phase 2A

Abide Therapeutics

1 program

Phase 2A

Asarina Pharma

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

33 of 34 classified programs — the dominant modality here.

3%ALL OTHERSCell therapy13%

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 100% of 34 pipeline programs.

Analysis

Trial Status

40

clinical trials

Completed27 · 68%
Terminated6 · 15%
Not yet recruiting3 · 8%
Withdrawn2 · 5%
Active, not recruiting1 · 3%
Unknown status1 · 3%

Clinical Trials

Trial Activity

40 trials

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
Active, not recruiting·NNoema Pharma AG·Phase 2·NCT06315751·164 enrolled
Study on the Mechanism of Pei Tu Ning Feng Tang in Alleviating Tourette Syndrome Via Functional Near-Infrared Spectroscopy (fNIRS) and the DA-MAPK-BDNF Pathway
Not yet recruiting·—·N/A·NCT07417371·60 enrolled
SCI-110 in the Treatment of Tourette Syndrome
Not yet recruiting·NNeurothera Labs Inc.·Phase 2·NCT05126888·164 enrolled
Transcranial Ultrasound Stimulation for Tourette Syndrome
Not yet recruiting·UUniversity of Calgary·Phase 1·NCT07699783·20 enrolled
Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder
Completed·AAbide Therapeutics·Phase 2·NCT03625453·50 enrolled
Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004652·20 enrolled
A Study to Explore the Effect of Sepranolone in Tourette Syndrome
Completed·AAsarina Pharma·Phase 2·NCT05434546·26 enrolled
Methylphenidate for Treating Children With ADHD and Tourette Syndrome
Completed·SStony Brook University·N/A·NCT00441649·71 enrolled
Ecopipam Treatment of Tourette Syndrome
Completed·PPsyadon Pharma·Phase 1/2·NCT01244633·18 enrolled
A Randomized, Placebo-controlled, Tourette Syndrome Study.
Completed·—·Phase 3·NCT00206323·29 enrolled
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
Completed·Teva logoTeva·Phase 2/3·NCT03452943·119 enrolled
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
Completed·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 2·NCT02679079·98 enrolled
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Completed·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 2·NCT03325010·127 enrolled
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
Completed·Teva logoTeva·Phase 3·NCT03571256·158 enrolled
Randomized Study of Pergolide in Children With Tourette Syndrome
Completed·—·N/A·NCT00004433·74 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)